Seoulin Bioscience Co.Ltd (038070) — Working Capital to Net Assets Ratio
Seoulin Bioscience Co.Ltd (038070) has a Working Capital to Net Assets ratio of 46.9% as of December 2025. Working capital of ₩40.37 Billion (current assets of ₩72.04 Billion minus current liabilities of ₩31.67 Billion) is measured against net assets of ₩86.05 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Seoulin Bioscience Co.Ltd balance sheet quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Seoulin Bioscience Co.Ltd Working Capital to Net Assets (2014–2025)
This chart shows how Seoulin Bioscience Co.Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of December 2025, the ratio stands at 46.9%, reflecting working capital of ₩40.37 Billion against net assets of ₩86.05 Billion KRW. Check 038070 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Seoulin Bioscience Co.Ltd (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Seoulin Bioscience Co.Ltd from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Seoulin Bioscience Co.Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 46.9% | ₩40.37 Billion | ₩86.05 Billion | ₩72.04 Billion | ₩31.67 Billion | ▼ -8.2 pp |
| 2024 | 55.1% | ₩46.21 Billion | ₩83.89 Billion | ₩59.84 Billion | ₩13.63 Billion | ▲ +1.0 pp |
| 2023 | 54.1% | ₩44.92 Billion | ₩83.06 Billion | ₩72.95 Billion | ₩28.03 Billion | ▲ +6.0 pp |
| 2022 | 48.1% | ₩40.30 Billion | ₩83.79 Billion | ₩86.67 Billion | ₩46.36 Billion | ▼ -53.5 pp |
| 2021 | 101.6% | ₩76.04 Billion | ₩74.86 Billion | ₩100.85 Billion | ₩24.81 Billion | ▲ +55.0 pp |
| 2020 | 46.6% | ₩27.93 Billion | ₩59.92 Billion | ₩41.46 Billion | ₩13.53 Billion | ▼ -0.4 pp |
| 2019 | 47.0% | ₩28.07 Billion | ₩59.71 Billion | ₩43.80 Billion | ₩15.73 Billion | ▲ +9.8 pp |
| 2018 | 37.2% | ₩20.01 Billion | ₩53.72 Billion | ₩32.77 Billion | ₩12.76 Billion | ▲ +0.3 pp |
| 2017 | 36.9% | ₩19.02 Billion | ₩51.49 Billion | ₩31.95 Billion | ₩12.93 Billion | ▼ -14.7 pp |
| 2016 | 51.6% | ₩25.08 Billion | ₩48.60 Billion | ₩36.02 Billion | ₩10.94 Billion | ▼ -7.4 pp |
| 2015 | 59.0% | ₩26.73 Billion | ₩45.30 Billion | ₩41.28 Billion | ₩14.55 Billion | ▼ -2.2 pp |
| 2014 | 61.2% | ₩26.41 Billion | ₩43.14 Billion | ₩39.67 Billion | ₩13.25 Billion | — |